Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) agonist BI 456906.

BI 456906 produced a placebo-corrected bodyweight loss of 13.8% (Week 16), highlighting potential to promote clinically meaningful bodyweight loss in people with overweight/obesity. This article is protected by copyright. All rights reserved.